These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22948883)

  • 21. Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication.
    Huang P; Goff DA; Huang Q; Martinez A; Xu X; Crowder S; Issakani SD; Anderson E; Sheng N; Achacoso P; Yen A; Kinsella T; Darwish IS; Kolluri R; Hong H; Qu K; Stauffer E; Goldstein E; Singh R; Payan DG; Lu HH
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1419-29. PubMed ID: 18227176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors.
    Mittapalli GK; Jackson A; Zhao F; Lee H; Chow S; McKelvy J; Wong-Staal F; Macdonald JE
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6852-5. PubMed ID: 21978675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner.
    Lee M; Yang J; Park S; Jo E; Kim HY; Bae YS; Windisch MP
    Antiviral Res; 2016 Aug; 132():287-95. PubMed ID: 27387825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retinoid derivative Tp80 exhibits anti-hepatitis C virus activity through restoration of GI-GPx expression.
    Nguyen BN; Okuno Y; Ajiro M; Iida K; Denawa M; Yamamoto M; Sakamoto N; Kagechika H; Hagiwara M
    J Med Virol; 2017 Jul; 89(7):1224-1234. PubMed ID: 27922182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well.
    Mondal R; Koev G; Pilot-Matias T; He Y; Ng T; Kati W; Molla A
    Antiviral Res; 2009 Apr; 82(1):82-8. PubMed ID: 19174175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple effects of Honokiol on the life cycle of hepatitis C virus.
    Lan KH; Wang YW; Lee WP; Lan KL; Tseng SH; Hung LR; Yen SH; Lin HC; Lee SD
    Liver Int; 2012 Jul; 32(6):989-97. PubMed ID: 22098176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemical genetics-based development of small molecules targeting hepatitis C virus.
    Jin G; Lee J; Lee K
    Arch Pharm Res; 2017 Sep; 40(9):1021-1036. PubMed ID: 28856597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection.
    Gastaminza P; Whitten-Bauer C; Chisari FV
    Proc Natl Acad Sci U S A; 2010 Jan; 107(1):291-6. PubMed ID: 19995961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Pawlotsky JM; Chevaliez S; McHutchison JG
    Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oligonucleotide-based therapeutic options against hepatitis C virus infection.
    Trepanier JB; Tanner JE; Alfieri C
    Antivir Ther; 2006; 11(3):273-87. PubMed ID: 16759043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Procyanidin B1 purified from Cinnamomi cortex suppresses hepatitis C virus replication.
    Li S; Kodama EN; Inoue Y; Tani H; Matsuura Y; Zhang J; Tanaka T; Hattori T
    Antivir Chem Chemother; 2010 Aug; 20(6):239-48. PubMed ID: 20710064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity.
    Bachmetov L; Gal-Tanamy M; Shapira A; Vorobeychik M; Giterman-Galam T; Sathiyamoorthy P; Golan-Goldhirsh A; Benhar I; Tur-Kaspa R; Zemel R
    J Viral Hepat; 2012 Feb; 19(2):e81-8. PubMed ID: 22239530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay.
    O'Boyle DR; Nower PT; Lemm JA; Valera L; Sun JH; Rigat K; Colonno R; Gao M
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1346-53. PubMed ID: 15793110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of natural compounds extracted from crude drugs as novel inhibitors of hepatitis C virus.
    Zheng X; Guo R; Liu Q; Wakae K; Watanabe N; Fukano K; Que L; Li Y; Aly HH; Watashi K; Suzuki R; Murayama A; Kato T; Aizaki H; Wakita T; Huang X; Yan Y; Song SJ; Muramatsu M
    Biochem Biophys Res Commun; 2021 Aug; 567():1-8. PubMed ID: 34130179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antiviral activity of polyprenylphosphates in experimental infection caused by hepatitis C virus in vitro].
    Narovlianskiĭ AN; Deriabin PG; Sedov AM; Sanin AV; Pronin AV
    Zh Mikrobiol Epidemiol Immunobiol; 2012; (5):81-4. PubMed ID: 23163044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and characterization of a novel HCV inhibitor targeting the late stage of HCV life cycle.
    Park SB; Boyer A; Hu Z; Le D; Liang TJ
    Antivir Ther; 2019; 24(5):371-381. PubMed ID: 30880685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SELECTIVE INHIBITION OF HEPATITIS C VIRUS REPLICATION BY ALPHA-ZAM, A
    Oyero OG; Toyama M; Mitsuhiro N; Onifade AA; Hidaka A; Okamoto M; Baba M
    Afr J Tradit Complement Altern Med; 2016; 13(6):144-148. PubMed ID: 28480371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
    Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N
    Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. (-)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus.
    Chen C; Qiu H; Gong J; Liu Q; Xiao H; Chen XW; Sun BL; Yang RG
    Arch Virol; 2012 Jul; 157(7):1301-12. PubMed ID: 22491814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A fluorescence-based high-throughput screen to identify small compound inhibitors of the genotype 3a hepatitis C virus RNA polymerase.
    Eltahla AA; Lackovic K; Marquis C; Eden JS; White PA
    J Biomol Screen; 2013 Oct; 18(9):1027-34. PubMed ID: 23708123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.